MarketPeel
Insider Trading Intelligence
CB

Camille L. Bedrosian

RYTM
DIRECTOR · RHYTHM PHARMACEUTICALS, INC. · CIK 0001326969
FILING MIX · LIFETIME61%/39%
BUYS
43
SELLS
27
TOTAL VALUE
$8.61M
COMPANIES
4
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
326,447
AVG SELL PX
$61.52
TRADE KIND
SHOWING 70 / 70
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
17 backtested trades · 8 horizons · 10 pending
Forward-return performance of every backtestable P/S trade by Camille L. Bedrosian, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d17+76.47%-2.47%-0.52%-1.96%-1.18%
14d17+52.94%-1.71%+0.04%-1.74%-1.79%
30d17+52.94%+0.08%+0.77%-0.69%-2.47%
60d17+58.82%+0.31%+3.51%-3.20%-8.37%
90d17+70.59%-8.92%+3.85%-12.94%-25.16%
180d17(1 pending)+87.50%+0.72%+4.78%-3.99%-29.13%
1y17(3 pending)+71.43%+23.22%+6.30%+16.93%-32.51%
2y17(6 pending)+100.00%-52.21%+11.46%-63.68%-65.03%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RYTM · 4,712 shares · as of Jun 24, 2025
09,25018,50027,75037,00020212022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 43 buys / 27 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
9,7309,730Jun 18, 2026Jun 22, 2026View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
5,92522,225Jun 18, 2026Jun 22, 2026View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
143,985143,985Mar 5, 2026Mar 9, 2026View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
95,990265,285Mar 5, 2026Mar 9, 2026View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
6,461$14.58$94.2K169,295Mar 2, 2026Mar 4, 2026View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
6,580$14.35$94.4K175,756Dec 1, 2025Dec 3, 2025View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
12,039$14.58$175.5K182,336Sep 30, 2025Oct 2, 2025View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
7,0377,037Jun 24, 2025Jun 26, 2025View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
4,7124,712Jun 24, 2025Jun 26, 2025View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
SALE
4,0000Jun 18, 2025Jun 23, 2025View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASE
4,0007,000Jun 18, 2025Jun 23, 2025View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,90016,300Jun 11, 2025Jun 13, 2025View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
10,35010,350Jun 11, 2025Jun 13, 2025View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
12,425$3.47$43.1K194,375Mar 31, 2025Apr 2, 2025View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
102,630102,630Mar 6, 2025Mar 10, 2025View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
68,420206,800Mar 6, 2025Mar 10, 2025View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
5,421$5.54$30.0K138,380Dec 2, 2024Dec 4, 2024View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
SALE
Chief Medical Officer
11,442$3.20$36.6K143,801Sep 30, 2024Oct 2, 2024View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASE
3,0003,000Jun 21, 2024Jun 25, 2024View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
SALE
3,0000Jun 21, 2024Jun 25, 2024View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
4,0004,000Jun 18, 2024Jun 20, 2024View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
14,00014,000Jun 18, 2024Jun 20, 2024View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,50012,500Jun 7, 2024Jun 11, 2024View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
3,4009,400Jun 7, 2024Jun 11, 2024View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
120,000120,000Apr 16, 2024Apr 18, 2024View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
96,910155,243Apr 16, 2024Apr 18, 2024View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
58,33358,333Nov 27, 2023Nov 29, 2023View →
AMLX
AMYLYX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
162,500162,500Nov 27, 2023Nov 29, 2023View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
3,0003,000Jun 21, 2023Jun 23, 2023View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
14,00014,000Jun 21, 2023Jun 23, 2023View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
17,50017,500Jun 16, 2023Jun 21, 2023View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,0006,000Jun 16, 2023Jun 21, 2023View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
2,66350,601Mar 1, 2023Mar 3, 2023View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
3,881$45.25$175.6K46,720Mar 1, 2023Mar 3, 2023View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
17,50017,500Jun 17, 2022Jun 21, 2022View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
20,00020,000Jun 8, 2022Jun 10, 2022View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
14,00047,938Mar 1, 2022Mar 3, 2022View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
24,90024,900Mar 1, 2022Mar 3, 2022View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
2,821$66.62$187.9K33,938Mar 1, 2022Mar 3, 2022View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
1,657$66.30$109.9K36,759Jan 30, 2022Feb 1, 2022View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
359$81.14$29.1K38,416Oct 14, 2021Oct 18, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
2,50053,000Sep 2, 2021Sep 2, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
2,500$100.18$250.4K38,775Sep 2, 2021Sep 2, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASE
EVP and Chief Medical Officer
2,500$55.00$137.5K41,275Sep 2, 2021Sep 2, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASE
EVP and Chief Medical Officer
2,500$55.00$137.5K41,275Sep 1, 2021Sep 2, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
2,500$100.03$250.1K38,775Sep 1, 2021Sep 2, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
2,50055,500Sep 1, 2021Sep 2, 2021View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
17,50017,500Jun 22, 2021Jun 23, 2021View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 9, 2021Jun 11, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
364$113.67$41.4K38,775May 6, 2021May 10, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
5,000$109.09$545.5K39,139Apr 15, 2021Apr 19, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
5,00058,000Apr 15, 2021Apr 19, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASE
EVP and Chief Medical Officer
5,000$55.00$275.0K44,139Apr 15, 2021Apr 19, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
4,63643,682Mar 1, 2021Mar 3, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
5,50039,046Mar 1, 2021Mar 3, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
11,00011,000Mar 1, 2021Mar 3, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
4,543$138.18$627.8K39,139Mar 1, 2021Mar 3, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
2,243$140.36$314.8K33,546Jan 30, 2021Feb 2, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASE
EVP and Chief Medical Officer
25,000$55.00$1.38M60,789Jan 15, 2021Jan 19, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
25,000$139.18$3.48M35,789Jan 15, 2021Jan 19, 2021View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
25,00063,000Jan 15, 2021Jan 19, 2021View →
RYTM
RHYTHM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
37,00037,000Dec 9, 2020Dec 11, 2020View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
262$88.00$23.1K35,789Oct 14, 2020Oct 16, 2020View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Sep 1, 2020Sep 3, 2020View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
249$66.26$16.5K36,051May 6, 2020May 8, 2020View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
21,00021,000Mar 1, 2020Mar 3, 2020View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
1,249$56.08$70.0K36,300Mar 1, 2020Mar 3, 2020View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
5,63437,549Mar 1, 2020Mar 3, 2020View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
7,30031,915Mar 1, 2020Mar 3, 2020View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
EVP and Chief Medical Officer
1,624$53.23$86.4K24,615Jan 30, 2020Jan 31, 2020View →
Other insiders · RYTM
Loading peer insiders…
About this filer
CIK 0001326969
ROLE
Director
PRIMARY
RYTM
COMPANIES
4
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001326969DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback